Lexeo Therapeutics, Inc.
LXEO
$4.61
-$0.12-2.54%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -109.31M | -98.33M | -86.60M | -77.22M | -69.42M |
| Total Depreciation and Amortization | 2.03M | 2.00M | 1.97M | 1.92M | 1.87M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.83M | 12.45M | 10.03M | 7.38M | 5.51M |
| Change in Net Operating Assets | 5.45M | 2.73M | 7.79M | 4.96M | 6.05M |
| Cash from Operations | -88.00M | -81.15M | -66.81M | -62.95M | -55.99M |
| Capital Expenditure | -296.00K | -481.00K | -554.00K | -474.00K | -300.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -77.99M | -93.60M | -13.00K | -63.00K | -58.00K |
| Cash from Investing | -78.28M | -94.08M | -567.00K | -537.00K | -358.00K |
| Total Debt Issued | -- | -- | 0.00 | 4.00M | 4.00M |
| Total Debt Repaid | -460.00K | -410.00K | -399.00K | -395.00K | -424.00K |
| Issuance of Common Stock | 6.90M | 95.49M | 189.43M | 189.42M | 189.05M |
| Repurchase of Common Stock | -17.00K | -17.00K | -13.00K | -13.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.29M | -6.29M | -75.00K | -86.00K | -86.00K |
| Cash from Financing | 133.00K | 88.78M | 188.94M | 192.93M | 192.54M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -166.15M | -86.45M | 121.57M | 129.44M | 136.20M |